A federal court in Texas has bolstered Novo Nordisk’s efforts to limit the production and sale of compounded versions of its GLP-1 drugs, Wegovy and Ozempic. Here are five notes: ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month, enhancing access for self-paying ...

One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk’s outlook is brightening. Novo Nordisk, the Danish company that produces the semaglutide ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Some adverse experiences were more common in the semaglutide group, including nausea, diarrhea, constipation and vomiting. "Novo Nordisk continues to explore semaglutide across metabolic and ...

In a statement, a Novo Nordisk spokesperson said the disease is “very rare,” and is not considered an adverse drug reaction to semaglutide drugs such as Ozempic, Wegovy and Rybelsus.

The U.S. Food and Drug Administration has accepted Novo Nordisk’s application for an ... for a once-a-day 25 milligram pill form of the semaglutide for chronic weight management, according ...

They are large molecule drugs, so complex in structure and must be administered by ... operates in the same manner as these market-leading products. Novo Nordisk offers a pill version of semaglutide, ...

Novo Nordisk A/S NVO is seeking FDA approval for ... efficacy and safety profile similar to once-weekly injectable semaglutide 2.4 milligram.” During the trial, adults struggling with obesity ...

Novo Nordisk's (NVO) investors are worried its ... showed 80 million prescriptions for copycat semaglutide were filled in the past year. That, Jørgensen said, is why the company missed its ...